Cancers, Год журнала: 2024, Номер 16(23), С. 4048 - 4048
Опубликована: Дек. 2, 2024
Lung cancer, a malignant neoplasm originating from the epithelial cells of lung, is characterized by its aggressive growth and poor prognosis, making it leading cause cancer-related mortality globally [...].
Язык: Английский
Frontiers in Oncology, Год журнала: 2024, Номер 14
Опубликована: Сен. 26, 2024
Lung cancer is a leading cause of cancer-related deaths globally, and traditional chemotherapy has limited efficacy in treating advanced non-small cell lung (NSCLC). In recent years, the prognosis for patients with NSCLC significantly improved due to development new treatment modalities, including targeted therapies. Targeted therapies utilize monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), or small molecule tyrosine kinase inhibitors (TKIs) directed against specific mutated genes such as EGFR ALK. The these drugs deepened our understanding outcomes patients. This review aims summarize mechanisms current status therapy NSCLC, discuss strategies overcome acquired resistance, address challenges field.
Язык: Английский
Процитировано
6
Bioorganic Chemistry, Год журнала: 2025, Номер 156, С. 108185 - 108185
Опубликована: Янв. 18, 2025
Язык: Английский
Процитировано
0
International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 2049 - 2049
Опубликована: Фев. 26, 2025
Lung cancer is one of the most common malignant cancers in countries and leading cause death among diseases worldwide. Despite constant progress diagnosis therapy, survival rates patients diagnosed with lung remain unsatisfactory. Numerous epidemiological experimental studies conducted as early 1970s confirm that important risk factor for development long-term smoking, which remains valid to this day. In paper, authors present latest data on epidemiology, pathogenesis, treatment molecular aspects cancer. last decade, many alterations are effective have been discovered. adenocarcinoma, tyrosine kinase inhibitors were developed EGFR mutations ALK ROS1 translocations approved use advanced stage adenocarcinomas. case squamous cell carcinoma, evaluation these not yet being used clinical practice. addition, there ongoing concerning potential therapeutic targets, such ROS, MET, FGFR, DDR-2 RET. Constant diagnostic methods gives rise hopes an improved prognosis
Язык: Английский
Процитировано
0
Expert Opinion on Drug Delivery, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Introduction Non-small cell lung cancer (NSCLC) continues to pose a considerable health challenge with few therapeutic alternatives. Liquid crystalline nanoparticles (LCN) are nanostructured drug delivery systems made of lipid-based amphiphilic materials that self-assemble into phases in aqueous environments. LCN have become promising way treat NSCLC owing their specific properties make them useful for targeted and controlled release.
Язык: Английский
Процитировано
0
Clinica Chimica Acta, Год журнала: 2025, Номер unknown, С. 120215 - 120215
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Current Opinion in Pulmonary Medicine, Год журнала: 2025, Номер unknown
Опубликована: Март 19, 2025
Purpose of review Mucosal-associated invariant T-cells (MAIT) have been associated with lung cancer and pulmonary infections. The treatment patients or infections includes host-directed therapies (HDTs). MAIT play a role in shaping the ‘milieu interne’ this addresses biology pathophysiology. Recent findings represent an attractive target for therapy malignancies are often difficult to exploit therapeutically due diversity both T-cell receptor (TCR) repertoire its ligandome. MAIT-cells restricted by major histocompatibility complex class I-related gene protein (MR1) that presents nondefined tumor-associated targets, bacterial products, vitamin drug derivates. Due their plasticity expression, able conversely switch from IFN-γ IL-17 production. Both cytokines key protective immune responses malignancies. MAIT-derived production interleukin (IL)-17/TGF-β shapes tumor micro-environment (TME), including tissue re-modelling leading fibrosis recruitment neutrophils. contribute gut-lung axis clinical improved checkpoint inhibition therapy. at crossroad HDTs targeting malignant infected cells. Clinical presentations overt inflammation, re-modeling reviewed along balance between Th1, Th2, Th9, Th17 immune-suppression Summary shape TME Drugs affect can be explored achieve results while curbing tissue-damaging responses.
Язык: Английский
Процитировано
0
Journal of Analytical Oncology, Год журнала: 2025, Номер 14, С. 4 - 12
Опубликована: Апрель 4, 2025
Introduction: Lung cancer is the most commonly occurring worldwide accounting for 12.4% of total new cases and also leading cause deaths (18.7%). In India, accounts 5.8% 8.2% deaths. Chemotherapy Radiation therapy plays a major role in treatment especially inoperable cases. this study we evaluated factors which could affect Overall Survival (OS) Disease -Free (DFS) patients with carcinoma treated by Sequential Chemoradiation (CTRT) Concurrent CTRT. Materials Method: A retrospective review was carried out on 38 who were either or CTRT at our institute. Various like age, gender, habits, disease laterality, histology, group stage, received radiation dose evaluated. Results analysed using IBM SPSS Statistics version 25 Kaplan-Meier curves. Results: Median age 65 years. The majority men (89.4 %) smokers (57.8%). Adenocarcinoma (63.2%) common histological type followed Squamous cell (18.4%) Small (18.4%). Majority left-sided tumors (52.6%). Most stage IIIA (44.7%) IIIB (39.5%). (78.9%) rest (21.1%). mean used 61.82Gy (Range: 45Gy-66Gy). 2-year OS DFS all 21% 18.4% respectively 5-year 13.1% 10.5% respectively. better diagnosed young (36-45 years), females, non-smokers, left-sidedtumors, but not statistically significant except Stage (p=0.007) left-sidedtumors (p=0.029) had significantly Conclusion: Young tumors, histology are favorable prognostic patients. Left-sided DFS.
Язык: Английский
Процитировано
0
Applied Sciences, Год журнала: 2025, Номер 15(8), С. 4507 - 4507
Опубликована: Апрель 19, 2025
Lung cancer remains a leading cause of global mortality, with early detection being critical for improving the patient survival rates. However, applying machine learning and deep effectively lung prediction using symptomatic lifestyle data requires careful consideration feature selection model optimization, which is not consistently addressed in existing research. This research addresses this gap by systematically evaluating comparing predictive efficacy several models, employing rigorous preprocessing, including Pearson’s correlation, outlier removal, normalization, on symptom factor dataset from Kaggle. Machine classifiers, Decision Trees, K-Nearest Neighbors, Random Forest, Naïve Bayes, AdaBoost, Logistic Regression, Support Vector Machines, were implemented Weka simultaneously neural network models 1, 2, 3 hidden layers, developed Python within Jupyter Notebook environment. The performance was assessed K-fold cross-validation 80/20 train/test splitting. results highlight importance enhancing accuracy demonstrate that single-hidden-layer network, trained 800 epochs, achieved 92.86%, outperforming models. study contributes to developing more effective computational methods detection, ultimately supporting improved outcomes.
Язык: Английский
Процитировано
0
Lung Cancer, Год журнала: 2024, Номер 198, С. 108026 - 108026
Опубликована: Ноя. 17, 2024
This systematic review explored the feasibility and impact of interventions using commercial activity monitors to track physical health-related outcomes during lung cancer treatment. Inclusion criteria focused on studies involving commercially available trackers that provided monitoring feedback patients. The devices selected were popular models, including Fitbit, Garmin, Apple, Samsung, Polar. Studies assessing reliability or validity these trackers, as well qualitative studies, protocols, non-English publications, those featuring non-commercial devices, excluded. Additionally, incorporating with other (e.g., robotic surgery) excluded if exercise could not be analysed independently. Searches conducted across various electronic databases, Cochrane Database Systematic Reviews, CINAHL Complete®, Science Citation Index, Google Scholar, Scopus, IEEE Xplore, PubMed, covering period from January 2000 November 2023. quality was assessed Risk Bias in Non-randomised Interventions (ROBINS-I) Randomised Trials (RoB 2.0) tools. Twelve met inclusion criteria, utilising wearable technology for patients over an average 6.3 ± 4.7 weeks. A key limitation this wide variation how implemented studies. Yet, significantly improved daily levels intensity, life, psychological impact, function compared usual care. These show promise predicting, monitoring, detecting activity, motivating patients, aiding recovery. However, limitations exist, further evidence is needed confirm their efficacy primary tools
Язык: Английский
Процитировано
1
Applied Sciences, Год журнала: 2024, Номер 14(21), С. 9658 - 9658
Опубликована: Окт. 22, 2024
The therapeutic potential of combining 5-FU with repurposed drugs such as Sildenafil, Tezosentan, Levosimendan, and Resveratrol was investigated in lung cancer treatment using the A549 cell line. This study aimed to enhance efficacy while mitigating side effects overcoming drug resistance. cytotoxic were assessed via MTT assay, an IC50 value 5.03 µM for cells. Subsequent experiments evaluated impact aforementioned on viability, clonogenic potential, morphology. results demonstrated that Sildenafil Tezosentan modestly improved efficacy, Levosimendan reduced viability by 40% (p < 0.01) over 50% 0.001), clonogenicity up 60% 0.001). These findings suggest or offers promising approaches therapy, potentially reducing need higher doses minimizing associated toxicity. Future studies are warranted elucidate mechanisms underlying these interactions assess their clinical relevance.
Язык: Английский
Процитировано
0